人表皮生长因子受体2低表达状态在局限高危和寡转移性前列腺腺癌中的表达及临床病理特点
Expression and clinicopathological features of human epidermal growth factor receptor 2-low local-ized high-risk and oligometastatic prostate adenocarcinoma
陈志强 1高宇 1杜松良 1牛少曦 1江彬 1贾通宇 1王保军 1张旭1
作者信息
- 1. 解放军总医院第三医学中心泌尿外科医学部,北京 100039
- 折叠
摘要
目的 探究人表皮生长因子受体2低表达状态(Her-2-Low)在局限高危和寡转移性前列腺腺癌中的表达特点,为Her-2抗体耦联药物的应用提供数据支持.方法 分析2021年8月至2023年4月解放军总医院泌尿外科行机器人辅助前列腺根治性切除术的患者共计100例,根据术前内分泌治疗与否分为内分泌治疗组(17例)和未内分泌治疗组(83例),根据转移状态分为局限高危组(71例)和寡转移组(29例),对其Her-2免疫组织化学染色结果进行统计学分析,采用秩和检验比较计量资料差异,表达率的差异比较采用卡方检验.结果 Her-2-Low在局限高危和寡转移性前列腺腺癌中表达率约为59％,并未发现免疫组织化学3+结果;Her-2-Low的表达率上,内分泌治疗组显著高于未内分泌治疗组[82.4％(14/17)比54.2％(45/83),x2=4.618,P＜0.05].寡转移组显著高于局限高危组[75.9％(22/29)比 52.1％(37/71),x2=4.801,P＜0.05].结论 Her-2-Low 在局限高危和寡转移性前列腺腺癌有较高的表达率,在术前接受内分泌治疗的高危和寡转移患者中可能存在更多Her-2抗体耦联药物敏感患者.
Abstract
Objective The aim of this study was to investigate the expression characteristics of hu-man epidermal growth factor receptor 2-Low(Her-2-Low)in limited high-risk and oligometastatic prostate adenocarcinomas.The findings will provide data to support the application of Her-2-targeted agents.Methods A total of 100 patients who underwent robotic-assisted radical prostatectomy at the Department of Urology,People's Liberation Army(PLA)General Hospital from August 2021 to April 2023 were retro-spectively analysed and divided into the Androgen Deprivation Therapy(ADT)group(n=17)and non-ADT group(n=83)according to preoperative treatment or not,and into the localized high-risk group(n=71)and the oligometastatic group(n=29)according to metastatic status.The results of their Her-2 immu-nohistochemical staining were statistically analysed,Differences in measures were compared using the rank sum test,and differences in expression rates were compared using the chi-square test.Results Her-2-Low was expressed in approximately 59％of localized high-risk and oligometastatic prostate adenocarcinomas and no immunohistochemical 3+results were found;The rate of Her-2-Low expression was significantly higher in the ADT-treated group compared to the non-ADT-treated group[82.4％(14/17)vs.54.2％(45/83),x2=4.618,P＜0.05].Additionally,the oligometastatic group had a significantly higher rate of expression compared to the limited high-risk group[75.9％(22/29)vs.52.1％(37/71),x=4.801,P＜0.05].Conclusion Her-2-Low has a high expression rate in localized high-risk and oligometastatic prostate adenocarcinoma.There may be a higher proportion of trastuzumab-deruxtecan-sensitive patients in the group of patients with preoperative endocrine therapy and oligometastases.
关键词
前列腺腺癌/人表皮生长因子受体2低表达状态/高危前列腺癌/寡转移Key words
Prostate adenocarcinoma/Human epidermal growth factor receptor 2-Low/High-risk prostate cancer/Oligometastatic引用本文复制引用
出版年
2024
NETL
NSTL
万方数据